Chongqing Genrix Biopharmaceutical Co., Ltd. (SHA:688443)
China · Delayed Price · Currency is CNY 31.20
+0.13 (0.42%)
At close: May 12, 2026
SHA:688443 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -564.33 | -535.65 | -797.27 | -801.32 | -576.37 | -322.13 |
Depreciation & Amortization | 70.87 | 70.87 | 66.65 | 59.17 | 49.94 | 38.5 |
Other Amortization | 5.1 | 5.1 | 7.94 | 4.61 | 3.69 | 5.56 |
Loss (Gain) From Sale of Assets | 4.51 | 4.51 | 0 | - | -0 | - |
Asset Writedown & Restructuring Costs | -3.55 | -3.55 | 0.54 | 0 | 0 | 0.7 |
Loss (Gain) From Sale of Investments | -8.83 | -8.83 | -2.73 | -1.94 | -7.86 | -4.13 |
Provision & Write-off of Bad Debts | - | - | 0.63 | - | - | -0.03 |
Other Operating Activities | 5.85 | 31.88 | 29.51 | 34.01 | 33.99 | 32.15 |
Change in Accounts Receivable | 6.06 | 6.06 | -40.88 | 9.88 | -7.71 | -105.1 |
Change in Inventory | -45.01 | -45.01 | 4.69 | 1.85 | -22.67 | -17.81 |
Change in Accounts Payable | 136.72 | 136.72 | 1.73 | 51.1 | 55.87 | 131.8 |
Change in Other Net Operating Assets | - | - | 153.76 | 265.07 | 293.47 | 2.68 |
Operating Cash Flow | -392.62 | -337.91 | -575.44 | -377.58 | -177.64 | -237.82 |
Capital Expenditures | -108.39 | -85.42 | -45.32 | -90.98 | -146.21 | -112.7 |
Sale of Property, Plant & Equipment | 0.15 | 0.1 | 0.04 | - | - | 0 |
Investment in Securities | -116.83 | -264.2 | -382.28 | 211.6 | 194.2 | -409.24 |
Other Investing Activities | 9.7 | 8.83 | 0.14 | - | 3.4 | 1.12 |
Investing Cash Flow | -215.38 | -340.7 | -427.42 | 120.62 | 51.4 | -520.82 |
Short-Term Debt Issued | - | - | - | - | - | 73.32 |
Long-Term Debt Issued | - | 892.25 | 212.91 | 109.63 | 208.35 | 186.79 |
Total Debt Issued | 955.06 | 892.25 | 212.91 | 109.63 | 208.35 | 260.11 |
Short-Term Debt Repaid | - | - | - | - | - | -499.15 |
Long-Term Debt Repaid | - | -660.92 | -23.39 | -257.25 | -14.88 | -9.07 |
Total Debt Repaid | -672.68 | -660.92 | -23.39 | -257.25 | -14.88 | -508.22 |
Net Debt Issued (Repaid) | 282.38 | 231.33 | 189.52 | -147.62 | 193.48 | -248.11 |
Issuance of Common Stock | - | - | - | 3,308 | - | 1,000 |
Repurchase of Common Stock | - | - | -14.68 | - | - | - |
Common Dividends Paid | -31.21 | -30.51 | -28.67 | -35.02 | -32.1 | -21.59 |
Other Financing Activities | -16.14 | -19.93 | - | -25.41 | - | - |
Financing Cash Flow | 235.03 | 180.88 | 146.17 | 3,100 | 161.37 | 730.3 |
Foreign Exchange Rate Adjustments | -0.02 | 0.01 | - | - | - | - |
Net Cash Flow | -372.99 | -497.71 | -856.69 | 2,843 | 35.13 | -28.34 |
Free Cash Flow | -501.02 | -423.33 | -620.75 | -468.56 | -323.85 | -350.52 |
Free Cash Flow Margin | -180.34% | -183.48% | -2062.65% | -38675.98% | -68143.75% | -894.41% |
Free Cash Flow Per Share | -1.37 | -1.15 | -1.69 | -1.46 | -1.18 | -1.27 |
Cash Income Tax Paid | 9.5 | 7.79 | 4 | -21.69 | -57.48 | -17.5 |
Levered Free Cash Flow | -293.37 | -233.74 | -413.65 | -267.97 | -190.87 | -715.31 |
Unlevered Free Cash Flow | -293.37 | -233.74 | -395.59 | -246.1 | -170.4 | -695.05 |
Change in Working Capital | 97.77 | 97.77 | 119.3 | 327.89 | 318.97 | 11.57 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.